Related Experiment Videos
Eptastigmine improves eight-arm radial maze performance in aged rats
D Braida1, F Ottonello, M Sala
1Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milan, Via Vanvitelli 32, Milan, 20129, Italy.
Pharmacological Research
|September 16, 2000
Summary
Eptastigmine, a cholinesterase inhibitor, improved memory deficits in aging rats. Long-term treatment showed lasting benefits in middle-aged rats, suggesting potential for age-related memory loss.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Age-related memory deficits are a growing concern.
- Cholinergic hypofunction is implicated in cognitive decline.
- Eptastigmine is a potent cholinesterase inhibitor.
Purpose of the Study:
- To investigate the efficacy of eptastigmine in ameliorating age-related memory impairment.
- To evaluate both acute and subchronic effects of eptastigmine on cognitive function in aging rats.
Main Methods:
- Wistar rats of various ages (3-27 months) were used.
- Radial arm maze task assessed learning and memory.
- Acute and subchronic administration of eptastigmine was employed.
Main Results:
- Eptastigmine reversed memory impairment in acute tests across all ages.
- Subchronic treatment improved maze performance in 18-month-old rats.
- Sustained cognitive benefits were observed up to 23 months in previously treated rats.
Conclusions:
- Eptastigmine effectively corrects age-related memory deficits.
- The drug shows promise in managing cognitive decline associated with aging.
- Potential therapeutic applications for cholinergic hypofunction-related memory loss.